FoundationOne™ Test Registry Study (FMI Registry)
This study is a prospective, multicenter, observational study to characterize utilization patterns of the FoundationOne™ test by oncologists under conditions of routine clinical practice in the US. The study will also examine impact of test results on subsequent clinical decisions regarding choice of therapy. The planned duration of the study is at least 2 years with 1 year for patient recruitment and a minimum 1-year follow-up period for each patient. Any patient for whom the treating physician has ordered a FoundationOne™ test and a report is delivered is eligible for participation on the study. Eligible patients from participating sites will be enrolled sequentially during the 1-year enrollment period. Sites will be required to maintain an enrollment log of all patients for whom the FoundationOne™ test has been ordered and document patient disposition and reasons for non-participation. All treatment decisions and clinical assessment will be made at the discretion of the treating physician per usual care and are not mandated by study design or protocol. Informed consent will be obtained from eligible patients prior to study entry.
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||1 Year|
|Official Title:||A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test|
- Composite characterization of current real-world practice patterns in the use of the FoundationOne™ test and the effect of the FoundationOne™ test on clinical decision making across the US [ Time Frame: Minimum 1 year follow-up ] [ Designated as safety issue: No ]
Characterization of practice patterns for the use of the test described by:
- Provider and site characteristics of patients receiving the FoundationOne test
- Socio-demographic and clinical characteristics of patients receiving the FoundationOne test
Examination of the effect of the test on clinical decision making by describing:
- Subsequent treatment patterns for patients after receipt of test results
- Clinician report outcomes regarding how test results guided clinical decision making
- Exploratory endpoints describing clinical outcomes in the study population [ Time Frame: Minimum 1 year follow-up ] [ Designated as safety issue: No ]
- Overall survival
- 1-year survival
- Overall progression-free survival (PFS)
|Study Start Date:||March 2013|
|Estimated Study Completion Date:||March 2015|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
FoundationOne™ Test Ordered
Patients for whom a FoundationOne™ test was ordered and a report is delivered.
Molecular testing of tumors, using techniques such as next-generation sequencing (NGS), facilitates an individualized approach to cancer treatment by sub-classifying diseases on an individual basis. Physicians can utilize an in depth understanding of disease at a molecular level to optimize therapy by selecting the most appropriate drugs and therapeutic targets. Genomic profiling has identified multiple genomic aberrations that are predictive markers for treatment response with targeted therapeutics.
FoundationOne™ is a commercially available molecular diagnostics test, for all solid tumor types, that analyzes routine clinical specimens for somatic alterations in relevant cancer-related genes. This validated in vitro diagnostic test, is performed in a single Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) approved laboratory at Foundation Medicine, Inc. It provides individualized, potentially actionable information regarding a patient's molecular cancer subtype that can be used by physicians to tailor treatment options.
With the recent commercial availability of the FoundationOne™ test, knowledge gaps exist regarding practice patterns associated with the use of this test in routine clinical practice and the impact of this test on clinical decision making. There is limited information regarding physician and patient characteristics that determine which patients receive the test, rationale for patient selection, and how physicians interpret and use the test results. Findings from this study will help to optimize patient selection and maximize the clinical impact of the test in terms of guiding therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01851213
|Contact: Norma Palma, PhDfirstname.lastname@example.org|
|United States, Washington|
|Spokane, Washington, United States, 99218|
|Principal Investigator: Stephen Anthony, MD|
|Principal Investigator:||Gary Palmer, MD||Sr VP Medical Afairs|